Modeling Price Increases and the Effects on Customer Segments

Size: px
Start display at page:

Download "Modeling Price Increases and the Effects on Customer Segments"

Transcription

1 Modeling Price Increases and the Effects on Customer Segments CBI Medicaid Congress May 9, 2017 Jennifer English Director, Pricing, Contracting and Govt Programs, Insmed, Inc.

2 Disclaimer The opinions and interpretations expressed during today s presentation are those of the individual presenter and do not reflect the policies or practices of any employer; present or past. The opinions do not constitute legal, financial, regulatory or fiduciary advice. Please consult your retained advisors or internal counsel with any questions. Additionally, the information and opinions shared by presenters today are their own and not to be attributed to current or prior employers.

3 Topics: Overview of GTN categories most impacted by Price Increases Understanding the impact of Price Increases on Government Pricing Programs Understanding the Evolution of Managed Care Controls and Contract Price Protection terms Understanding Price Protection Systems to Support the Process 3

4 Overview of GTN categories most impacted by Price Increases 4

5 Components of Gross-to-Net Gross-to-Net Categories Definitions Prompt Pay Discount Prompt Pay Discount is offered and taken by all direct customers and is typically 1-2%. Wholesaler/Distributor Fees Chargebacks Medicaid Rebates Other Government Rebates (IFF, Tricare) Commercial Payer Rebates Medicare Part D Payer Rebates Medicare Part D CGDP Co-pay Mitigation Allowance for Returns Bona Fide Service Fees for Inventory Management and Administration of pricing contracts. Federally mandated price concessions to the VA/DOD under the FSS, Covered Entities under the 340B/PHS and institutional customers under GPO contracts. Discount will increase over time to the extent that price increases exceed the rate of inflation (CPI-U). Federally mandated rebates to state Medicaid programs. Discount will increase over time to the extent that price increases exceed the rate of inflation (CPI-U), in addition to States expanding Medicaid Lives due to ACA. Includes rebates paid for Tricare utilization, as well as the quarterly VA IFF fee payments. Rebate payments to Commercial plans, includes Base Rebates, Admin Fees and Price Protection Penalty Rebates. Rebate payments to Medicare Part D plans, includes Base Rebates and Price Protection Penalty Rebates. Federally mandated payments to cover 50% of patient costs in the Medicare Part D Coverage Gap (note, 50% of patient co-pay does not equal 50% of WAC). Co-pay mitigation for patients with co-pay >$X. Manufacturer co-pays amount down to $X. Assume Rx mix will shift to higher co-insurance benefit design by X% each year. Based on product Returns Goods Policy and contract terms negotiations. 5

6 Components of Gross-to-Net Gross-to-Net Categories Definitions Prompt Pay Discount Prompt Pay Discount is offered and taken by all direct customers and is typically 1-2%. Wholesaler/Distributor Fees Bona Fide Service Fees for Inventory Management and Administration of pricing contracts. Chargebacks Medicaid Rebates Other Government Rebates (IFF, Tricare) Commercial Payer Rebates Medicare Part D Payer Rebates Medicare Part D CGDP Co-pay Mitigation Federally mandated price concessions to the VA/DOD under the FSS, Covered Entities under the 340B/PHS and institutional customers under GPO contracts. Discount will increase over time to the extent that price increases exceed the rate of inflation (CPI-U). FSS & PHS Federally mandated rebates to state Medicaid programs. Discount will increase over time to the extent that price increases exceed the rate of inflation (CPI-U), in addition to States expanding Medicaid Lives due to ACA. CPI-U & BP Price increases are the predominant driver of GTN growth in Government Mandated Programs Includes rebates paid for Tricare utilization, as well as the quarterly VA IFF fee payments. Rebate payments to Commercial plans, includes Base Rebates, Admin Fees and Price Protection Penalty Rebates. PP rebates Rebate payments to Medicare Part D plans, includes Base Rebates and Price Protection Penalty Rebates. Federally mandated payments to cover 50% of patient costs in the Medicare Part D Coverage Gap (note, 50% of patient co-pay does not equal 50% of WAC. Donut hole (Price Inflation Penalties) Co-pay mitigation for patients with co-pay >$X. Manufacturer co-pays amount down to $X. Assume Rx mix will shift to higher co-insurance benefit design by X% each year. Allowance for Returns Based on product Returns Goods Policy and contract terms negotiations. 6

7 Components of Gross-to-Net Gross-to-Net Categories Definitions Prompt Pay Discount Prompt Pay Discount is offered and taken by all direct customers and is typically 1-2%. Wholesaler/Distributor Fees Chargebacks Medicaid Rebates Other Government Rebates (IFF, Tricare) Commercial Payer Rebates Medicare Part D Payer Rebates Medicare Part D CGDP Co-pay Mitigation Allowance for Returns Bona Fide Service Fees for Inventory Management and Administration of pricing contracts. Federally mandated price concessions to the VA/DOD under the FSS, Covered Entities under the 340B/PHS and institutional customers under GPO contracts. Discount will increase over time to the extent that price increases exceed the rate of inflation (CPI-U). GPO/Institutional Expansion of % of Contracted Customers with Rebate/Price Discounts as well as pressure for higher discount levels drive GTN growth in Payer Channel Federally mandated rebates to state Medicaid programs. Discount will increase over time to the extent that price increases exceed the rate of inflation (CPI-U), in addition to States expanding Medicaid Lives due to ACA. Includes rebates paid for Tricare utilization, as well as the quarterly VA IFF fee payments. Rebate payments to Commercial plans, includes Base Rebates, Admin Fees and Price Protection Penalty Rebates. Value based & PP rebates Rebate payments to Medicare Part D plans, includes Base Rebates and Price Protection Penalty Rebates. Federally mandated payments to cover 50% of patient costs in the Medicare Part D Coverage Gap (note, 50% of patient co-pay does not equal 50% of WAC. Co-insurance Co-pay mitigation for patients with co-pay >$X. Manufacturer co-pays amount down to $X. Assume Rx mix will shift to higher co-insurance benefit design by X% each year. (Commercial and Medicare Part D) Based on product Returns Goods Policy and contract terms negotiations. 7

8 Understanding the impact of Price Increases on Government Pricing Programs

9 Government Programs Medicaid Federal Supply Schedule 340B/PHS Model impact to AMP Project range of rate quarterly growth for CPI-U Project Commercial BP impact due to increasing discounts and price protection rates Project URA Project Rx growth Model impact to NFAMP and FCP Project range of rate annual growth for CPI-U Understand the incentives to shift Rx from TriCare rebate to FSS price Discount differences: WAC minus FCP > NFAMP minus FCP Use AMP and URA projections to model PHS discount ranges Project growth in Rx due to increase in covered entity eligibility Understand growth of entity relationships with Contracted Pharmacies and potential for double dipping 9

10 Understanding the Evolution of Managed Care Price Protection 10

11 What Price Increases? 11

12 Price Protection From a Payer s Perspective Source: The Express Scripts 2014 Drug Trend Report 12

13 Price Protection From a Payer s Perspective Given the already high cost of specialty drugs, rapidly increasing prices are a critical concern. One of Prime s top initiatives is to contract with drug manufacturers who provide protection from high inflation trends. These contracts protect both customers and plan sponsors from higher-thanexpected increases in specialty drug prices and allow for more accurate forecasting of future drug costs. As pharmacy benefit managers and health plans strive to improve the quality of care for individuals with MS through improved adherence, the expected increases in cost of care can be mitigated through rebate contractual relationships that provide some measure of price inflation protection. Source: Prime Therapeutics 2012 Drug Trend Insights

14 Price Protection From a Payer s Perspective We use our Prescription Drug List (PDL) to provide access to safe, effective medications. While the PDL covers almost all prescription drugs, it uses cost-sharing based on placing drugs in differently priced tiers to encourage use of preferred treatments. The PDL works in tandem with such proven effective utilization management tools such as supply limits, prior authorization, step therapy and our negotiated price protection arrangements. Source: article Treatment and the high cost of MS

15 What is Price Protection? Price Inflation Agreement Price Protection Price Guarantee What Does it Mean? 15

16 What is Price Protection? Price Protection is a stipulation in a Commercial Payer or PBM contract that defines & limits the liability to a Payer or PBM by setting maximum Price Increase caps on a Manufacturer s product. The Payer or PBM is made whole for any increase above the defined Price cap in the form of additional penalty rebate from the Manufacturer to the Payer or PBM. 16

17 What is Price Protection? Price Protection is a stipulation in a Commercial Payer or PBM contract that defines & limits the liability to a Payer or PBM by setting maximum Price Increase caps on a Manufacturer s product. Manufacturer Ceiling Price to Cap The Payer or PBM is made whole for any Payer/PBM Product Cost Liability increase above the defined Price cap in the form of additional penalty rebate from the Manufacturer to the Payer or PBM. 17

18 Why Price Protection? Payers & PBMs want to protect themselves from the potential cost liability of aggressive price increases taken by Manufacturers This protection (ceiling cap) allows them the opportunity to budget appropriately and provide clarity on forecasted product cost liability over the next several years So competitive product formulary decisions they make today are still profitable several years from now 18

19 Why Price Protection? Payers & PBMs want to protect themselves from the potential cost liability of aggressive price increases taken by Manufacturers This protection (ceiling cap) allows them the opportunity More to Predictable budget appropriately Rx Costand provide clarity on forecasted product cost liability over the next several years So competitive product formulary decisions they make today are still profitable several years from now 19

20 Understanding Price Protection Calculations 20

21 Types of Price Protection Annual Reset Cumulative Cumulative & Perpetual * When compared head-to-head in Year 1 21

22 Types of Price Protection Annual Reset Cumulative Cumulative & Perpetual Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. * When compared head-to-head in Year 1 22

23 Types of Price Protection Annual Reset Cumulative Cumulative & Perpetual Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. * When compared head-to-head in Year 1 23

24 Types of Price Protection Annual Reset Cumulative & Cumulative Perpetual Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection * When compared head-to-head in Year 1 24

25 Types of Price Protection Annual Reset Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. 25

26 Types of Price Protection Annual Reset Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. 26

27 Types of Price Protection Annual Reset Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. Year 2 Baseline WAC resets with Year 1 Actual WAC 27

28 Types of Price Protection Annual Reset Allowed WAC increase is reset annually Results in slightly larger price protection rebate versus Allowed Net WAC * Does not provide long term protection from cumulative effect of increases that exceed allowed inflation. Year 2 Baseline WAC resets with Year 1 Actual WAC 28

29 Types of Price Protection Cumulative Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. 29

30 Types of Price Protection Cumulative Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. 30

31 Types of Price Protection Cumulative Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. Year 2 Baseline WAC resets with Year 1 Allowed WAC 31

32 Types of Price Protection Cumulative Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. Year 2 Baseline WAC resets with Year 1 Allowed WAC Penalty is the difference between Allowed Net WAC and Actual Net WAC 32

33 Types of Price Protection Cumulative Allowed Net WAC focuses on Net Cost after Rebate Results in slightly lower price protection rebate versus Allowed WAC * Provides long term cost predictability and protection from cumulative effect of higher than expected increases. Year 2 Baseline WAC resets with Year 1 Allowed WAC Penalty is the difference between Allowed Net WAC and Actual Net WAC 33

34 Types of Price Protection Cumulative & Perpetual Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection 34

35 Types of Price Protection Cumulative & Perpetual Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection 35

36 Types of Price Protection Cumulative & Perpetual Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection Year 2 Baseline WAC resets with Year 1 Actual WAC 36

37 Types of Price Protection Cumulative & Perpetual Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection Year 2 Baseline WAC resets with Year 1 Actual WAC Year 3 No WAC increase, 37

38 Types of Price Protection Cumulative & Perpetual Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection Year 2 Baseline WAC resets with Year 1 Actual WAC Year 3 No WAC increase, yet pay Year 1 & 2 Penalties 38

39 Types of Price Protection Cumulative & Perpetual Allowed Net WAC focuses on Net Cost after Rebate Once a penalty rebate is triggered, it is carried forward perpetually, even if NO WAC increase is taken in the future Provides long term cost predictability and protection Year 2 Baseline WAC resets with Year 1 Actual WAC Year 3 No WAC increase, yet pay Year 1 & 2 Penalties 39

40 Types of Price Protection Comparisons 40

41 Manufacturer View: Price Protection Analysis Annual Resetting Price Protection at 5%, baseline WAC = 12/31/16, take 9% Price Increase in CY2017 & 2018 Dec Q Q Q Q Q Q Q Q4 WAC $ $ $ $ $ $ $ $ $ Rebate % 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% Net Price $ $ $ $ $ $ $ $ $ Price Protection Factor 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% Allowed WAC per Unit $ $ $ $ $ $ $ $ Allowed Net Price $ $ $ $ $ $ $ $ Price Protection Rebate $ $ $ $ $ $ $ $ $ Price Protection Rebate % 3.3% 3.3% 3.3% 3.3% 3.3% 3.3% 3.30% 3.30% Total Net effective discount 13.3% 13.3% 13.3% 13.3% 13.3% 13.3% 13.3% 13.3% Annual Resetting Price Protection at 8%, baseline WAC = 12/31/16, take 9% Price Increase in CY2017 & 2018 Dec Q Q Q Q Q Q Q Q4 WAC $ $ $ $ $ $ $ $ $ Rebate % 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% Net Price $ $ $ $ $ $ $ $ $ Price Protection Factor 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% Allowed WAC per Unit $ $ $ $ $ $ $ $ Allowed Net Price $ $ $ $ $ $ $ $ Price Protection Rebate $ $ $ $ $ $ $ $ $ Price Protection Rebate % 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.83% 0.83% Total Net effective discount 10.8% 10.8% 10.8% 10.8% 10.8% 10.8% 10.8% 10.8% No PP, Increase base rebate to 12%, take 9% Price Increase in CY2017 & 2018 Dec Q Q Q Q Q Q Q Q4 WAC $ $ $ $ $ $ $ $ $ Rebate % 12.00% 12.00% 12.00% 12.00% 12.00% 12.00% 12.00% 12.00% 12.00% Net Price $ $ $ $ $ $ $ $ $ Price Protection Factor 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Allowed WAC per Unit $ - $ - $ - $ - $ - $ - $ - $ - Allowed Net Price $ - $ - $ - $ - $ - $ - $ - $ - Price Protection Rebate $ $ - $ - $ - $ - $ - $ - $ - $ - Price Protection Rebate % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00% 0.00% Total Net effective discount 12.0% 12.0% 12.0% 12.0% 12.0% 12.0% 12.0% 12.0% 41

42 Systems to Support 42

43 Systems Excel Based Systems Based Typically Small Pharma 1-12 NDC s One Business Unit 43

44 Systems Excel Based Systems Based Typically Small Pharma 1-12 NDC s One Business Unit Pros: Low Cost, One Owner, Universal Cons: Non Transferable, Time Consuming 44

45 Systems Excel Based Systems Based Typically Small Pharma 1-12 NDC s One Business Unit Typically Large Pharma 24+ NDC s Multiple Business Units 45

46 Systems Excel Based Systems Based Typically Small Pharma 1-12 NDC s One Business Unit Typically Large Pharma 24+ NDC s Multiple Business Units Pros: Replicable, Auditable, Scenario Build, Multiple Owners/Inputs Cons: High Cost, Compatibility with other Systems 46

47 Systems Excel Based Systems Based Hybrid Based Typically Small Pharma 1-12 NDC s One Business Unit Typically Large Pharma 24+ NDC s Multiple Business Units Some in Excel Others in System Examples: GP & Chargebacks in System Rebates & Price Protection in Excel 5/4/

48 Systems Excel Based Systems Based Hybrid Based Typically Small Pharma 1-12 NDC s One Business Unit Typically Large Pharma 24+ NDC s Multiple Business Units Some in Excel Others in System Examples: GP & Chargebacks in System Rebates & Price Protection in Excel Pros: Moderate to High Cost, Multiple Departments with One Owner, Pick and Choose Systems for Economic Efficiencies Cons: Potentially More Costly than System Approach from Man Power perspective, Time Consuming, Too Many Variables 48

49 D e c r e a s e d R i s k Excel Based Models One Size Fits All? Not Always Contract Variability Not Easy to Change Systems System Based Models Robust Flexible Scalable Easy to Incorporate Pre/Post Deal GTN Models Replicable, Accurate, Auditable Audit Proof Increased Accuracy Accurate 49

50 System impacts on Price Increase Decisions Data Management Modeling Accruals Brings together data from disparate systems onto the same page Limits individual workstream bottlenecks Data integrity maintained, not exposed to keying errors or Excel glitches Effortless audit process Easier to perform Price Increase What If comparisons Pre-Deal & Price Increase impact analytics Versioning control Find limits of and monitor Price Increase profitability More accurate reserves Efficient update of actuals vs accruals Easily compare veracity of accrual forecasting to improve future projections Reduced close and forecast cycle time 50

51 QUESTIONS?

52 Thank you for your attention!

Marc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance

Marc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance Marc Claussen, Chiesi USA, Director, Market Access Donna White, Chiesi USA, Sr. Director, Contracting and Compliance The views/observations expressed in this presentation are the personal views/observations

More information

Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary

Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary The Centers for Medicare & Medicaid Services (CMS) on February 2, 2012 published in the Federal Register a proposed rule

More information

BERKELEY RESEARCH GROUP. Executive Summary

BERKELEY RESEARCH GROUP. Executive Summary Executive Summary Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees

More information

Payer Channel Forecasting and Analysis. Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc.

Payer Channel Forecasting and Analysis. Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc. Payer Channel Forecasting and Analysis Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc. Disclaimer The views and opinions expressed in this presentation are those of

More information

BFSFs and FMV Under the Final Rule. February 22, 2016

BFSFs and FMV Under the Final Rule. February 22, 2016 BFSFs and FMV Under the Final Rule February 22, 2016 Today s Speakers Chris Coburn Managing Director Huron Consulting Group ccobourn@huronconsultinggroup.com 312-212-6710 John Shakow Partner King & Spalding

More information

THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE

THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE Donna Lee Yesner Morgan Lewis and Bockius Phone : 202.739.5887 Email: dyesner@morganlewis.com www.morganlewis.com BACKGROUND In

More information

The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape

The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape Lucas Greenwalt, Senior Principal Amundsen Consulting Prepared for: CBI Gross to Net Boot

More information

MEDICARE PLAN PAYMENT GROUP

MEDICARE PLAN PAYMENT GROUP DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: June 23, 2017 To: From: All Part

More information

How the Federal Government Can Help States Address Rising Prescription Drug Costs

How the Federal Government Can Help States Address Rising Prescription Drug Costs A PUBLICATION OF THE NATIONAL ACADEMY FOR STATE HEALTH POLICY February 2018 How the Federal Government Can Help States Address Rising Prescription Drug Costs Supported by The Commonwealth Fund Introduction

More information

Standing strong for payers and patients

Standing strong for payers and patients Standing strong for payers and patients Dr. Steve Miller, SVP, Chief Medical Officer Ben Bier, VP Investor Relations W I L L I A M B L A I R 3 7 TH ANNUAL G ROWTH STOCK C ONFERENCE 6.14.17 1 Safe harbor

More information

DIR: Trends, Issues, and Impending Impacts

DIR: Trends, Issues, and Impending Impacts DIR: Trends, Issues, and Impending Impacts Lari Harding Vice President, Product Marketing Chris Smith, R.Ph Director, Pharmacy Business Intelligence 1 Disclosures Lari Harding is the Vice President, Product

More information

Understanding Pharmacy Benefit Management Services

Understanding Pharmacy Benefit Management Services Understanding Pharmacy Benefit Management Services Peter Cullen VP, Business Development and Strategic Initiatives March 12, 2014 Innovation Session Overview and Learning Objectives Session Overview: Provide

More information

Appendix I: Data Sources and Analyses. Appendix II: Pharmacy Benefit Management Tools

Appendix I: Data Sources and Analyses. Appendix II: Pharmacy Benefit Management Tools Appendix I: Data Sources and Analyses This brief includes findings from analyses of the Centers for Medicare & Medicaid Services (CMS) State Drug Utilization Data 1 and CMS 64 reports for federal fiscal

More information

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016 Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress October 20, 2016 Thomas Beimers Hogan Lovells Thomas.beimers@hoganlovells.com Sarah Franklin Covington

More information

MEDICARE PLAN PAYMENT GROUP

MEDICARE PLAN PAYMENT GROUP DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: May 30, 2018 To: From: All Part D

More information

Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates

Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates October 2016 Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates A Study of Original Branded Products in the U.S. $ Introduction The cost of medicines in the U.S. has been the subject

More information

Standing strong for payers and patients

Standing strong for payers and patients Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE

More information

Health Reform Update: Focus on Prescription Drug Price Regulation

Health Reform Update: Focus on Prescription Drug Price Regulation International Life Sciences Arbitration Health Industry Alert If you have questions or would like additional information on the material covered in this Alert, please contact the author: Joseph W. Metro

More information

Impact of Medicaid MCO Claims on Forecasts and Accruals

Impact of Medicaid MCO Claims on Forecasts and Accruals Impact of Medicaid MCO Claims on Forecasts and Accruals 19 th Annual CBI Medicaid and Government Pricing Congress Tuesday, May 9, 2017 Partha Chatterjee Managing Partner pchatterjee@akaragroup.com (973)

More information

Pharmaceutical Summit on Business and Compliance Issues in Managed Markets

Pharmaceutical Summit on Business and Compliance Issues in Managed Markets Pharmaceutical Summit on Business and Compliance Issues in Managed Markets TRACK A: 340B PROGRAM CONSIDERATIONS A Panel Discussion By: Agenda Panel Introductions Overview of 340B Program Compliance Considerations

More information

Overview of Coverage of Drugs Under the Medicaid Medical Benefit

Overview of Coverage of Drugs Under the Medicaid Medical Benefit Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008 Amanda Bartelme Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Medical vs. Pharmacy

More information

Pharmacy Benefit Managers (PBMs)

Pharmacy Benefit Managers (PBMs) Pharmacy Benefit Managers (PBMs) Reducing Costs and Improving Quality Lauren Rowley, VP State Affairs National Conference of State Legislatures May 18, 2018 Overview What is the problem? What is a PBM?

More information

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE Moderator Audrey Halvorson, Vice Chairperson, Health Practice Council Presenters Karen Bender, Member, Prescription Drug

More information

Prescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007

Prescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007 Prescription Drugs Spending Distribution and Cost Drivers Steve Kappel January 25, 2007 Introduction Why Focus on Drugs? Compared to other health care spending: Even faster annual growth Higher reliance

More information

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS AN INNOVATIVE IDEA THAT CHANGED THE INDUSTRY In 2001, frustrated by the limitations and lack of transparency in the traditional pharmacy

More information

The Challenge of Drug Price Transparency

The Challenge of Drug Price Transparency The Challenge of Drug Price Transparency Mason Tenaglia, VP Payer & Managed Care Insights December 2016 Copyright 2016 QuintilesIMS. All rights reserved. Why is there a call for price transparency? Commercial

More information

TRICARE Pharmacy Voluntary Agreement for Retail Refunds (Additional Refund) for Uniform Formulary Placement (UF-VARR)

TRICARE Pharmacy Voluntary Agreement for Retail Refunds (Additional Refund) for Uniform Formulary Placement (UF-VARR) TRICARE Pharmacy Voluntary Agreement for Retail Refunds (Additional Refund) for Uniform Formulary Placement (UF-VARR) CAVEATS: The parties acknowledge that 32 C.F.R. 199.21(q), effective May 26, 2009 provides

More information

Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration

Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration Medicaid Drug Rebates Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration Medicaid Drug Rebates History of Medicaid Drug Rebates and Preferred Drug Lists Affordable

More information

SETTING A STANDARD FOR GP COMPLIANCE

SETTING A STANDARD FOR GP COMPLIANCE SETTING A STANDARD FOR GP COMPLIANCE CURRENT LANDSCAPE AND WHAT DOES GP COMPLIANCE LOOK LIKE? MAY 9, 2017 2017 HURON CONSULTING GROUP INC. SPEAKER INTRODUCTIONS Clay Willis Director T 404-825-3319 E cwillis@huronconsultinggroup.com

More information

PHARMACY BENEFIT MANAGER (PBM)

PHARMACY BENEFIT MANAGER (PBM) PHARMACY BENEFIT MANAGER (PBM) Presentation by: Pantea Ghasemi, USC Pharm.D. Candidate of 2015 Mentor: Dr. Craig Stern, Pro Pharma Consultants Inc. April 3, 2015 OBJECTIVES 1. Define PBM 2. Discuss Service

More information

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT AN INNOVATIVE IDEA THAT CHANGED THE INDUSTRY In 2001, frustrated by the limitations and lack of transparency in the traditional pharmacy

More information

Re: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs)

Re: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs) January 2, 2008 Reference No.: FASC08001 Kerry Weems Acting Administrator, Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200

More information

M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G

M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G H E A L T H W E A L T H C A R E E R M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G O H I O D E P A R T M E N T O F M E D I C A I D December 6, 2016 Presenters

More information

Pharmacy Program Management: Pitfalls, Challenges, and Best Practices About Solid Benefit Guidance specialty 60,000,000 covered member lives INSIDER

Pharmacy Program Management: Pitfalls, Challenges, and Best Practices About Solid Benefit Guidance specialty 60,000,000 covered member lives INSIDER Pharmacy Program Management: Pitfalls, Challenges, and Best Practices October 2, 2017 This presentation contains proprietary information and is not to be reproduced or further distributed without permission

More information

340B Drug Program Compliance: Focus on Disproportionate Hospitals

340B Drug Program Compliance: Focus on Disproportionate Hospitals 340B Drug Program Compliance: Focus on Disproportionate Hospitals Part II: 340B Drug Program Compliance: Pharmacy Operations and the DSH January 29, 2014 1 Faculty Stephen J. Weiser, JD, LLM Director 312-403-4284

More information

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES

More information

Submitted electronically via to

Submitted electronically via  to April 8, 2019 Mr. Aaron Zajic Office of Inspector General U.S. Department of Health and Human Services Attention: OIG-0936-P Room 5527, Cohen Building 330 Independence Avenue, SW Washington, DC 20201 Submitted

More information

Fourth Quarter 2016 Earnings Conference Call

Fourth Quarter 2016 Earnings Conference Call Fourth Quarter 2016 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 9, 2017 Revised 2/9 Forward-looking

More information

Prime therapeutics medicare part d preferred drug list 2017

Prime therapeutics medicare part d preferred drug list 2017 Prime therapeutics medicare part d preferred drug list 2017 Apr 28, 2018. Explore part D, part B formulary medication and non-formulary drug list.. Prior Authorization and Step Therapy criteria at Prime

More information

Average Sales Price and Medicare Part B. Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc.

Average Sales Price and Medicare Part B. Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc. Average Sales Price and Medicare Part B Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc. May, 2016 Disclaimer The views and opinions expressed in this presentation are those

More information

We applied the following methodology and assumptions changes to our original estimates:

We applied the following methodology and assumptions changes to our original estimates: 333 Clay Street Suite 4330 Houston, TX 77002 USA Tel +1 713 658 8451 Fax +1 713 658 9656 April 1, 2013 milliman.com Ms. Barbara Maxwell Deputy Director Texas Association of Health Plans 1001 Congress Avenue,

More information

CRS Report for Congress Received through the CRS Web

CRS Report for Congress Received through the CRS Web CRS Report for Congress Received through the CRS Web Order Code RS20295 August 9, 1999 Outpatient Prescription Drugs: Acquisition and Reimbursement Policies Under Selected Federal Programs Heidi G. Yacker

More information

MELINTA THERAPEUTICS, INC. (Exact name of registrant specified in its charter)

MELINTA THERAPEUTICS, INC. (Exact name of registrant specified in its charter) 3 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended

More information

KEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs)

KEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs) The Texas Association of Health Plans Representing health insurers, health maintenance organizations, and other related health care entities operating in Texas. KEEPING PRESCRIPTION DRUGS AFFORDABLE: The

More information

Assessing ACA Issues - The 40% Excise Tax and Other Employer Implications

Assessing ACA Issues - The 40% Excise Tax and Other Employer Implications Assessing ACA Issues - The 40% Excise Tax and Other Employer Implications April, 2016, IPMA-Employer Training Edward A. Kaplan, Segal Consulting Copyright 2016 by The Segal Group, Inc. All rights reserved.

More information

DIR FEES: WHAT YOU NEED TO KNOW JULY 13, :00 10:00 AM

DIR FEES: WHAT YOU NEED TO KNOW JULY 13, :00 10:00 AM DIR FEES: WHAT YOU NEED TO KNOW JULY 13, 2017 9:00 10:00 AM ACPE UAN: 0107-9999-17-078-L04-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon completion of this CPE

More information

Implement a definition of negotiated price to include all pharmacy price concessions.

Implement a definition of negotiated price to include all pharmacy price concessions. NCPA Analysis of Medicare Part D Pharmacy DIR Fee Reform Policy Proposal and Other Policies Impacting Community Pharmacies in the CMS Proposed Rule, Modernizing Part D and Medicare Advantage to Lower Drug

More information

Moving From PBM to PBA Model

Moving From PBM to PBA Model Moving From PBM to PBA Model Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Pro Pharma Pharmaceutical Consultants, Inc. Under the preceptorship of Dr. Craig Stern

More information

June Investor Presentation

June Investor Presentation June 2014 Investor Presentation Safe Harbor Certain statements included herein, including guidance and those that express management's objectives and the strategies to achieve those objectives, as well

More information

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January 2016 The Centers for Medicare & Medicaid Services (CMS) recently issued a 658-page, oftendelayed, final rule on the

More information

The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD

The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use Presented by Daniel Tomaszewski Pharmd, PhD 1 Medical Vs. Pharmacy Coverage Medical Insurance Managed by an Insurance

More information

Dual Pricing vs. Single Pricing

Dual Pricing vs. Single Pricing Dual Pricing vs. Single Pricing CBI CONFERENCE NOVEMBER 16, 2016 Agenda Definitions How, Why and When Dual Pricing works Dual vs. Single Pricing Benefits/Challenges Pricing Considerations 2 Definitions

More information

Unique PBM Capabilities

Unique PBM Capabilities Gaining Lives With Our Unique PBM Capabilities Jon Roberts Executive Vice President & President, CVS/caremark Agenda Performance Highlights Pharmacy Trends and Cost Management Programs Well Positioned

More information

TouchScript Medication Management System. Financial Impact Analysis on Pharmacy Risk Pools

TouchScript Medication Management System. Financial Impact Analysis on Pharmacy Risk Pools TouchScript Medication Management System Financial Impact Analysis on Pharmacy Risk Pools October 2000 Table of Contents Introduction 3 Executive Summary.. 4-5 Quantitative Analysis 6-10 TouchScript Impact

More information

Managing Specialty Pharmaceuticals: Balancing Access and Affordability

Managing Specialty Pharmaceuticals: Balancing Access and Affordability Managing Specialty Pharmaceuticals: Balancing Access and Affordability Commercial Health Plan Perspective The Health Industry Forum July 16, 2008 Presented by: Margaret M. (Peggy) Johnson, R.Ph. Vice President

More information

April 8, 2019 VIA Electronic Filing:

April 8, 2019 VIA Electronic Filing: April 8, 2019 VIA Electronic Filing: http://www.regulations.gov The Honorable Alex Azar Secretary Department of Health and Human Services 200 Independence Avenue SW, Room 600E Washington, D.C. 20201 Re:

More information

HEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036

HEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Curriculum Vitae HEATHER I. BATES Managing Director, BRG Health Analytics BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Direct: 202.480.2660 Cell: 202.641.1035 hbates@thinkbrg.com

More information

How ACO s Can Impact Contracting A Real World Example. Mike Medel Pharm D, MBA Banner Health

How ACO s Can Impact Contracting A Real World Example. Mike Medel Pharm D, MBA Banner Health How ACO s Can Impact Contracting A Real World Example Mike Medel Pharm D, MBA Banner Health Agenda Banner Pharmacy Services Introduction Accountable Care Organization Summary Basic Constructs of ACO Partnership

More information

Medicare Part D: TrOOP (True Out-Of-Pocket) Costs

Medicare Part D: TrOOP (True Out-Of-Pocket) Costs Medicare Part D: TrOOP (True Out-Of-Pocket) Costs Pantea Ghasemi, USC Pharm.D. Candidate of 2015 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1, 2015 Objectives 1. Review background

More information

340B Drug Pricing Program

340B Drug Pricing Program 340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY

More information

Delivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer

Delivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer Delivering Value for All Health Care Stakeholders Larry Merlo President & Chief Executive Officer Agenda Our Value Proposition Has Never Been Stronger We See Compelling Opportunities in a Robust Health

More information

Innovative Strategies for Managing the Rising Cost of Specialty Drugs

Innovative Strategies for Managing the Rising Cost of Specialty Drugs Innovative Strategies for Managing the Rising Cost of Specialty Drugs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 5, 2013 Managing the Rising Cost of Specialty Drugs

More information

The Management of Specialty Drugs: Opportunities and Challenges

The Management of Specialty Drugs: Opportunities and Challenges The Management of Specialty Drugs: Opportunities and Challenges Scott Woods Senior Director, Policy PCMA Innovations X April 5, 2016 Specialty Drugs to be Half of Spend by 2018 Forecast PMPM Net Drug

More information

Specialty Pharmacies. Ensuring Compliant Relationships. April 2017

Specialty Pharmacies. Ensuring Compliant Relationships. April 2017 Specialty Pharmacies Ensuring Compliant Relationships April 2017 Agenda I. Current climate II. Regulatory Overview III. Types of SPP relationships IV. Data purchase arrangements V. Fee for service arrangements

More information

DIR fees are knocking down pharmacy profits

DIR fees are knocking down pharmacy profits 16 America s PHARMACIST November 2016 DIR fees are knocking down pharmacy profits by Bruce A. Semingson, Pharmacist In 2016, retail pharmacy will pay between $360 million and $2.16 billion in direct and

More information

PRESCRIPTION DRUG PLANS. What is a PDP?

PRESCRIPTION DRUG PLANS. What is a PDP? PRESCRIPTION DRUG PLANS What is a PDP? PDP Since Original Medicare does not have prescription drug coverage built into it, Medicare beneficiaries must enroll into a plan that offers that coverage. Beneficiaries

More information

(PDP) 2016 Summary of benefits for our Medicare prescription drug plans (Standard and Enhanced)

(PDP) 2016 Summary of benefits for our Medicare prescription drug plans (Standard and Enhanced) (PDP) 2016 Summary of benefits for our Medicare prescription drug plans (Standard and Enhanced) Contract S5540, Plans 002 and 004 January 1, 2016 December 31, 2016 Y0079_7238 CMS Accepted 08312015 U5073g,

More information

Chapter 9 Medicaid and 340B

Chapter 9 Medicaid and 340B Chapter 9 Medicaid and 340B A. Introduction UPDATED 1. The complex intersection of Medicaid and 340B The intersection of 340B and Medicaid is one of the most complex and significant areas within any health

More information

Medicare Part D. Prescription Drug Insurance Coverage

Medicare Part D. Prescription Drug Insurance Coverage Medicare Part D Prescription Drug Insurance Coverage You Need To Know This outline shares the basics of Medicare Part D only. Other important information you will need to make decisions about your Medicare

More information

Uniform Formulary Solicitation, Price Quotes and Uniform Formulary Blanket Purchase Agreement

Uniform Formulary Solicitation, Price Quotes and Uniform Formulary Blanket Purchase Agreement Uniform Formulary Solicitation, Price Quotes and Uniform Formulary Blanket Purchase Agreement 1. PRICE QUOTE FOR INCLUSION ON UNIFORM FORMULARY: By submitting this Uniform Formulary Blanket Purchase Agreement

More information

2019 Summary of Benefits

2019 Summary of Benefits 2019 Summary of Benefits Jan. 1, 2019 Dec. 31, 2019 888-645-6025 TTY 711 Seven Days a Week, 8 A.M. to 8 P.M.(Oct. 1, 2018, to Mar. 31, 2019) Monday-Friday, 8 A.M. to 8 P.M. (All Other Times) (PDP) (PDP)

More information

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Jeffrey A. Bourret, M.S., R.Ph., FASHP Senior Director, Managed Markets Healthcare Systems Marketing

More information

Exploring the Interaction between Medicare Part B and Medicare Part D

Exploring the Interaction between Medicare Part B and Medicare Part D The National Medicare Prescription Drug Congress Exploring the Interaction between Medicare Part B and Medicare Part D Jennifer Breuer, Esq. Gardner, Carton & Douglas 191 N. Wacker Drive Chicago, IL 60606

More information

The Pros and Cons of Self-Funding Health Coverage

The Pros and Cons of Self-Funding Health Coverage The Pros and Cons of Self-Funding Health Coverage BY LARRY GRUDZIEN ATTORNEY AT LAW : Mar. 20, 2018 Pros and Cons of Self-Funding Health Coverage Self-Funding: What is it? Self-Funding in the Marketplace

More information

August 4, The Honorable Charles Rangel, Chairman Committee on Ways and Means United States House of Representatives Washington, D.C.

August 4, The Honorable Charles Rangel, Chairman Committee on Ways and Means United States House of Representatives Washington, D.C. August 4, 2009 The Honorable Charles Rangel, Chairman Committee on Ways and Means United States House of Representatives Washington, D.C. 20515 The Honorable Henry A. Waxman, Chairman Committee on Energy

More information

Florida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter October 1, 2017 through December 31, 2017

Florida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter October 1, 2017 through December 31, 2017 Florida Medicaid Prescribed Drug Service Spending Control Initiatives For the Quarter October 1, through December 31, Report to the Florida Legislature September 2018 [This page intentionally left blank.]

More information

Q Formulary Performance:

Q Formulary Performance: Insights Executive Briefing Issue 10, 2016 Q1 2016 Performance: Key Data to Consider as You Look Ahead to 2017 Increasingly our clients see proactive, dynamic formulary management as a necessary response

More information

August 11, Submitted electronically via Regulations.gov

August 11, Submitted electronically via Regulations.gov August 11, 2017 Submitted electronically via Regulations.gov Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1678-P PO Box 8013 Baltimore, MD 21244-1850

More information

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Amgen GLOBAL CORPORATE COMPLIANCE POLICY 1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract

More information

SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS

SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS The rising cost of drugs, fuelled by the growing specialty

More information

Pharmacy Benefit Management in Oncology

Pharmacy Benefit Management in Oncology Pharmacy Benefit Management in Oncology October 28 th, 2015 Business Health Care Group Protecting the Future of Oncology Care: A Community Conversation Brent Eberle RPh MBA Chief Pharmacy Officer, Navitus

More information

April 8, Dear Mr. Levinson,

April 8, Dear Mr. Levinson, April 8, 2019 Daniel Levinson Office of Inspector General Department for Health and Human Services Cohen Building, Room 5527 330 Independence Ave, SW Washington, DC 20201 Re: Fraud and Abuse; Removal of

More information

Medicaid Price Calculations & Rebates 1.0: Mastering the Essentials

Medicaid Price Calculations & Rebates 1.0: Mastering the Essentials ACI Rx Drug Pricing Master Course Medicaid Price Calculations & Rebates 1.0: Mastering the Essentials November 1, 2016 William Sarraille Sidley Austin LLP Rick Zimmerer KPMG LLP Disclaimer This presentation

More information

Federal Government Processes and Standards

Federal Government Processes and Standards Federal Government Processes and Standards Marci Anderson, VAOIG Mark Myers, VAOIG 1 VA Structure and Best Practices Procurement in VA is not centralized. Contracts and task orders are awarded by the Office

More information

Appendix. Year Total drug spending reaching catastrophic coverage, $

Appendix. Year Total drug spending reaching catastrophic coverage, $ Appendix Exhibit A. Low-income Subsidy Copayments in 2006-2012 Year 2006 2007 2008 2009 2010 2011 2012 Total drug spending reaching catastrophic coverage, $ 5100 5451.25 5726.25 6153.75 6440 6447.5 6657.5

More information

(PDP) 2015 Summary of benefits for our Medicare prescription drug plans (Enhanced and Standard)

(PDP) 2015 Summary of benefits for our Medicare prescription drug plans (Enhanced and Standard) (PDP) 2015 Summary of benefits for our Medicare prescription drug plans (Enhanced and Standard) Contract S5540, Plans 004 and 002 January 1, 2015 December 31, 2015 Y0079_6779 CMS Accepted 08312014 U5073b,

More information

Frequently Asked Questions about Health Care Reform and the Affordable Care Act

Frequently Asked Questions about Health Care Reform and the Affordable Care Act Frequently Asked Questions about Health Care Reform and the Affordable Care Act HEALTH CARE REFORM OVERVIEW Q 1: What ACA changes are already in place? There are no lifetime dollar limits on essential

More information

Medicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014

Medicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014 Medicaid Prescribed Drug Program Spending Control Initiatives For the Quarter April 1, 2014 through June 30, 2014 Report to the Florida Legislature January 2015 Table of Contents Purpose of Report... 1

More information

Patient Out-of-Pocket Assistance in Medicare Part D: Direct and Indirect Healthcare Savings

Patient Out-of-Pocket Assistance in Medicare Part D: Direct and Indirect Healthcare Savings Patient Out-of-Pocket Assistance in Medicare Part D: Direct and Indirect Healthcare Savings Avalere Health April 2018 Avalere Health T 202.207.1300 avalere.com An Inovalon Company F 202.467.4455 1350 Connecticut

More information

Pharmacy Benefit Strategies for Lowering Prescription Drug Costs

Pharmacy Benefit Strategies for Lowering Prescription Drug Costs Pharmacy Benefit Strategies for Lowering Prescription Drug Costs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 6, 2012 Pharmacy Benefit Strategies for Lowering Prescription

More information

Prescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017

Prescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017 Prescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017 Ronna Hauser, PharmD VP Pharmacy Affairs The strength of our numbers NCPA represents America's 22,000+

More information

Florida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter July 1, 2016 through September 30, 2016

Florida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter July 1, 2016 through September 30, 2016 Florida Medicaid Prescribed Drug Service Spending Control Initiatives For the Quarter July 1, through September 30, Report to the Florida Legislature March 2018 [This page intentionally left blank.] Table

More information

Pharmacy Benefit Managers Overview

Pharmacy Benefit Managers Overview Pharmacy Benefit Managers Overview A Presentation to the House Health Innovation Subcommittee Mary Alice Nye, Ph.D. Health and Human Services Staff Director, OPPAGA December 6, 2017 Pharmacy Benefit Managers

More information

Today PBMs control the pharmacy benefits of more than 253 MILLION Americans.

Today PBMs control the pharmacy benefits of more than 253 MILLION Americans. The PBM Story Decades ago, insurance companies expanded their coverage to include prescription drugs. They turned to a new kind of company, a sort of middleman, to process prescription drug claims. For

More information

Today PBMs control the pharmacy benefits of more than 253 MILLION. 3 PBMs. Americans.

Today PBMs control the pharmacy benefits of more than 253 MILLION. 3 PBMs. Americans. The PBM Story Decades ago, insurance companies expanded their coverage to include prescription drugs. They turned to a new kind of company, a sort of middleman, to process prescription drug claims. For

More information

THANK YOU SPONSORS 2

THANK YOU SPONSORS 2 1 THANK YOU SPONSORS 2 How to: Power Up your pharmacy benefit plan Brent Matthews, Benefits Advisor/Principal, TrueNorth Companies Aaron Viertel, Director of Clinical Management, TrueNorth Companies 3

More information

Pharmacy Billing and Reimbursement

Pharmacy Billing and Reimbursement FSHP Disclosure Pharmacy Billing and Tara L McNulty RPhT, CPhT I, Tara McNulty, do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies

More information

Best Practice Recommendation for

Best Practice Recommendation for Best Practice Recommendation for Exchanging & Processing about Pharmacy Benefit Management Version 020915a Issue Date Version Explanation 10-20-2014 First Release 02-09-15 Clarify language under Health

More information

CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting

CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting Avalere Health An Inovalon Company February 28, 2017 Growth in Drug Costs Relative to

More information

Introduction. 5 Strategies to Help Navigate Health Care Reform NOW

Introduction. 5 Strategies to Help Navigate Health Care Reform NOW Introduction The Patient Protection and Affordable Care Act (ACA) and the Health Care and Education Act of 2010 commonly referred to as Health Care Reform is now a definitive reality, bringing with it

More information